According to the ROADS trial, GammaTile cesium-131 brachytherapy boosts local control and survival in brain cancer treatment, matching SRT safety while avoiding radiation delays. Intraoperative cesium ...
Combination tobevibart 300 mg + elebsiran 200 mg q4w achieved HDV RNA TND in 77% at week 72 and 88% at week 96, outperforming tobevibart monotherapy. Profound HBsAg lowering occurred with dual therapy ...
Accelerating private equity “roll-up” consolidation can evade antitrust thresholds, and post-acquisition staffing reductions have been associated with higher hospital-acquired conditions, falls, ...
Escalating expenditures in stage ≥3 CKD and especially kidney failure made KRT the predominant cost driver, amplifying value from therapies that delay dialysis or transplantation. Finerenone was ...
MajesTEC-9 randomized 593 patients (median age 70; median two prior lines) to teclistamab or investigator’s choice PVd or Kd; 80% lenalidomide-refractory, 85% anti-CD38–refractory. Interim analysis ...
Chronic hand eczema is common, heterogeneous, and frequently occupational, with high rates of sick leave, job disruption, and notable annual per-patient societal costs in the United States. Diagnostic ...
This supplement was supported by AstraZeneca. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...
This article provides a commentary on a news feature published on AJMC.com in 2025 titled “AI Seen as Key to Reducing Health Care Claim Denials, Survey Finds.” We read with interest a feature article ...
FDA approval establishes durvalumab plus BCG induction and maintenance as a new immunotherapy-based option for BCG-naïve, high-risk NMIBC following TURBT, potentially redefining the frontline ...
Absence of a scalp-specific cancer excess challenges the UV-exposure hypothesis and supports maintaining standard, individualized skin cancer risk assessment rather than AA-specific screening ...
Integrated SWIFT-1/2 enrolled 762 patients with type 2 asthma; depemokimab 100 mg SC q26 weeks achieved clinically meaningful exacerbation reductions versus placebo. Comorbid CRSwNP predicted greater ...
Fragmented subspecialty care and underbuilt survivorship pathways risk overwhelming primary care as the survivor population ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results